Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIα

Blood

Volumn 98, Issue 3, 2001, Pages 830-833

  Baker, Ronda K ^a,b,c   Kurz, Ebba U ^a,b,c   Pyatt, David W ^a,b,c   Irons, Richard D ^a,b,c   Kroll, David J ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BENZOQUINONE; 4,4' DIHYDROXYBIPHENYL; ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; BIPHENYL DERIVATIVE; CATECHOL; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; HYDROQUINONE; PEROXIDASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOGENETICS; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; METABOLIC REGULATION; MOLECULAR STABILITY; PRIORITY JOURNAL;

EID: 0035437139     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.830     Document Type: Article

References (27)

1. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J. 1994;303:681-695.
2. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta. 1998;1400:233-255.
3. Goldstein BD. Hematotoxicity in humans. J Toxicol Environ Health. 2000;2(suppl):69-105.
4. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992;19:47-84.
5. Sammett D, Lee EW, Kocsis JJ, Snyder R. Partial hepatectomy reduces both metabolism and toxicity of benzene. J Toxicol Environ Health. 1979;5:785-792.
6. Valentine JL, Lee SS, Seaton MJ, et al. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicol Appl Pharmacol. 1996;141:205-213.
7. Johansson I, Ingelman-Sundberg M. Benzene metabolism by ethanol-, acetone-, and benzene-inducible cytochrome P-450 (IIE1) in rat and rabbit liver microsomes. Cancer Res. 1988;48:5387-5390.
8. Eastmond DA, Smith MT, Irons RD. An interaction of benzene metabolites reproduces the myelotoxicity observed with benzene exposure. Toxicol Appl Pharmacol. 1987;91:85-95.
9. Chen H, Eastmond DA. Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects. Carcinogenesis. 1995;16:2301-2307.
10. Baker RK, Pyatt DW, Irons RD, Kroll DJ. Catalytic inhibition of topoisomerase II alpha by benzene metabolites. Toxicologist. 2000;54:1655.
11. Gantchev TG, Hunting DJ. The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol. 1998;53:422-428.
12. Kurz EU, Leader KB, Kroll DJ, Clark M, Gieseler F. Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3-3epsilon. J Biol Chem. 2000;275:13948-13954.
13. Eastmond DA, Smith MT, Ruzo LO, Ross D. Metabolic activation of phenol by human myeloperoxidase and horseradish peroxidase. Mol Pharmacol. 1986;30:674-679.
14. Irons RD, Greenlee WF, Wierda D, Bus JS. Relationship between benzene metabolism and toxicity: a proposed mechanism for the formation of reactive intermediates from polyphenol metabolites. Adv Exp Med Biol. 1981;136 Pt A:229-243.
15. Berger NA, Chatterjee S, Schmotzer JA, Helms SR. Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc Natl Acad Sci U S A. 1991;88:8740-8743.
16. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351-375.
17. Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci U S A. 2000;97:4790-4795.
18. Neece SH, Carles-Kinch K, Tomso DJ, Kreuzer KN. Role of recombinational repair in sensitivity to an antitumour agent that inhibits bacteriophage T4 type II DNA topoisomerase. Mol Microbiol. 1996;20:1145-1154.
19. Xue Y, Guo Y, Xie X. Translocation t(7;11)(p15; p15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis. Leuk Res. 1997;21:107-109.
20. Yager JW, Eastmond DA, Robertson ML, Paradisin WM, Smith MT. Characterization of micronuclei induced in human lymphocytes by benzene metabolites. Cancer Res. 1990;50:393-399.
21. Stillman WS, Varella-Garcia M, Gruntmeir JJ, Irons RD. The benzene metabolite, hydroquinone, induces dose-dependent hypoploidy in a human cell line. Leukemia, 1997;11:1540-1545.
22. Stillman WS, Varella-Garcia M, Irons RD. The benzene metabolite, hydroquinone, selectively induces 5q31- and -7 in human bone marrow cells. Exp Hematol. 2000;28:169-176.
23. Stillman WS, Varella-Garcia M, Irons RD. The benzene metabolites hydroquinone and catechol act in synergy to induce dose-dependent hypoploidy and -5q31 in a human cell line. Leuk Lymphoma. 1999;35:269-281.
24. Zhang L, Wang Y, Shang N, Smith MT. Benzene metabolites induce the loss and long arm deletion of chromosomes 5 and 7 in human lymphocytes. Leuk Res. 1998;22:105-113.
25. Irons RD, Neptun DA. Effects of the principal hydroxy-metabolites of benzene on microtubule polymerization. Arch Toxicol. 1980;45:297-305.
26. Irons RD, Neptun DA, Pfeifer RW. Inhibition of lymphocyte transformation and microtubule assembly by quinone metabolites of benzene: evidence for a common mechanism. J Reticuloendothel Soc. 1981;30:359-372.
27. Irons RD, Pfeifer RW, Aune TM, Pierce CW. Soluble immune response suppressor (SIRS) inhibits microtubule function in vivo and microtubule assembly in vitro. J Immunol. 1984;133:2032-2036